Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:

Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?

Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?

Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.

Participants will:

Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure

Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure

Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother

A subset of participants will provide blood samples at selected time points to measure serum prolactin levels